Astellas’s Long-Term Safety Data Could Boost Fezolinetant’s Approval Chances
With a pair of successful Phase III pivotal studies in hand, the Japanese pharma reports that its nonhormonal hot flash/night sweats candidate demonstrated safety and tolerability over 52 weeks.
You may also be interested in...
While Daiichi Sankyo reveals ambitious plan with Enhertu, Chugai shows stable growth plans with COVID-19 drugs, Astellas reacted to concerns over Xtandi’s slow growth with enthusiastic investment plan for the next potential star.
In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are nine new products for endocrine and metabolic disorders that could make their debuts next year.
Astellas lays out new mid-term strategic plan it sees as overcoming looming major expiries while positioning the firm for growth in new areas and a more than doubling in market cap.